Pages that link to "Q74594355"
Jump to navigation
Jump to search
The following pages link to A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia (Q74594355):
Displaying 50 items.
- Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis (Q22251177) (← links)
- Glutamatergic drugs for schizophrenia (Q24246163) (← links)
- Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review (Q24598636) (← links)
- Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes (Q24606088) (← links)
- D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review (Q26781321) (← links)
- The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia (Q28081110) (← links)
- Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia (Q28240120) (← links)
- Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia (Q28248687) (← links)
- Consolidation of human motor cortical neuroplasticity by D-cycloserine (Q28267127) (← links)
- Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment (Q30428213) (← links)
- D-cycloserine: an evolving role in learning and neuroplasticity in schizophrenia (Q30450078) (← links)
- Prepulse inhibition and genetic mouse models of schizophrenia (Q30478270) (← links)
- Review of cognition and brain structure in schizophrenia: profiles, longitudinal course, and effects of treatment (Q30918894) (← links)
- D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia (Q33845745) (← links)
- Association of schizophrenia onset age and white matter integrity with treatment effect of D-cycloserine: a randomized placebo-controlled double-blind crossover study (Q33900951) (← links)
- Glutamate and schizophrenia: beyond the dopamine hypothesis (Q33996803) (← links)
- Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study (Q34013820) (← links)
- Treatment of negative and cognitive symptoms (Q34108164) (← links)
- Differential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission (Q34230984) (← links)
- Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia? (Q34253250) (← links)
- The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia (Q34327773) (← links)
- Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs (Q34338202) (← links)
- A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia (Q34579324) (← links)
- Clinical perspectives on the combination of D-cycloserine and cognitive-behavioral therapy for the treatment of anxiety disorders. (Q34653283) (← links)
- Integrative role for serotonergic and glutamatergic receptor mechanisms in the action of NMDA antagonists: potential relationships to antipsychotic drug actions on NMDA antagonist responsiveness (Q34804420) (← links)
- Management of the negative symptoms of schizophrenia: new treatment options (Q35201017) (← links)
- Antagonists and agonists at the glycine site of the NMDA receptor for therapeutic interventions. (Q35204614) (← links)
- Glutamate as a therapeutic target in psychiatric disorders (Q35847653) (← links)
- The potential role of lamotrigine in schizophrenia (Q36185191) (← links)
- Augmentation strategies in clozapine-resistant schizophrenia (Q36268252) (← links)
- Treatment of schizophrenia negative symptoms: future prospects (Q36402997) (← links)
- Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions (Q36756365) (← links)
- Future perspectives on the treatment of cognitive deficits and negative symptoms in schizophrenia (Q36930839) (← links)
- Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site (Q36954416) (← links)
- MMP-9 Serum Levels in Schizophrenic Patients during Treatment Augmentation with Sarcosine (Results of the PULSAR Study). (Q37134495) (← links)
- Can small molecules provide truly effective enhancement of cognition? Current achievements and future directions (Q37867702) (← links)
- Glutamate receptor abnormalities in schizophrenia: implications for innovative treatments (Q38151703) (← links)
- D-cycloserine in Schizophrenia: New Strategies for Improving Clinical Outcomes by Enhancing Plasticity (Q38750121) (← links)
- Neuropsychiatric Effects of Antimicrobial Agents (Q39135986) (← links)
- Acute, but not chronic, exposure to d-cycloserine facilitates extinction and modulates spontaneous recovery of a conditioned taste aversion (Q39427245) (← links)
- Treatment of Comorbid Tuberculosis and Depression (Q39853786) (← links)
- Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone (Q42931511) (← links)
- Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series (Q44132352) (← links)
- Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial (Q44672181) (← links)
- High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia (Q44734491) (← links)
- Glycine and D: -serine, but not D: -cycloserine, attenuate prepulse inhibition deficits induced by NMDA receptor antagonist MK-801. (Q44850578) (← links)
- A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients (Q45122746) (← links)
- The cognitive effects of modulating the glycine site of the NMDA receptor with high-dose glycine in healthy controls (Q46922501) (← links)
- Acute or subchronic clozapine treatment does not ameliorate prepulse inhibition (PPI) deficits in CPB-K mice with low levels of hippocampal NMDA receptor density (Q48149992) (← links)
- Behavioral effects of orally administered glycine in socially housed monkeys chronically treated with phencyclidine (Q48225264) (← links)